HomeComparePINE vs BMY

PINE vs BMY: Dividend Comparison 2026

PINE yields 6.42% · BMY yields 4.17%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMY wins by $99.7K in total portfolio value
10 years
PINE
PINE
● Live price
6.42%
Share price
$18.00
Annual div
$1.16
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.8K
Annual income
$0.66
Full PINE calculator →
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →

Portfolio growth — PINE vs BMY

📍 BMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPINEBMY
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PINE + BMY cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PINE pays
BMY pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PINE
Annual income on $10K today (after 15% tax)
$545.42/yr
After 10yr DRIP, annual income (after tax)
$0.56/yr
BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
At 15% tax rate, BMY beats the other by $33,849.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PINE + BMY for your $10,000?

PINE: 50%BMY: 50%
100% BMY50/50100% PINE
Portfolio after 10yr
$70.7K
Annual income
$19,912.16/yr
Blended yield
28.18%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BMY right now

PINE
Analyst Ratings
1
Strong
9
Buy
2
Hold
Consensus: Buy
Price Target
$20.50
+13.9% upside vs current
Range: $20.00 — $21.00
Altman Z
0.5
Piotroski
4/9
BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PINE buys
0
BMY buys
0
No recent congressional trades found for PINE or BMY in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPINEBMY
Forward yield6.42%4.17%
Annual dividend / share$1.16$2.49
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%37%
Portfolio after 10y$20.8K$120.5K
Annual income after 10y$0.66$39,823.66
Total dividends collected$654.00$91.0K
Payment frequencyquarterlyquarterly
SectorREITHealthcare
Analyst consensusBuyHold
Analyst price target$20.50$62.73

Year-by-year: PINE vs BMY ($10,000, DRIP)

YearPINE PortfolioPINE Income/yrBMY PortfolioBMY Income/yrGap
1← crossover$11,021$320.83$11,271$571.12$250.00BMY
2$11,958$165.23$12,884$824.20$926.00BMY
3$12,878$83.77$14,993$1,206.32$2.1KBMY
4$13,822$42.16$17,839$1,797.27$4.0KBMY
5$14,811$21.14$21,826$2,738.11$7.0KBMY
6$15,858$10.59$27,643$4,289.31$11.8KBMY
7$16,973$5.30$36,534$6,955.64$19.6KBMY
8$18,164$2.65$50,861$11,770.13$32.7KBMY
9$19,437$1.32$75,402$20,980.23$56.0KBMY
10$20,798$0.66$120,504$39,823.66$99.7KBMY

PINE vs BMY: Complete Analysis 2026

PINEREIT

Alpine Income Property Trust, Inc. (NYSE: PINE) is a publicly traded real estate investment trust that acquires, owns and operates a portfolio of high-quality single-tenant net leased commercial income properties.

Full PINE Calculator →

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →
📬

Get this PINE vs BMY comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PINE vs SCHDPINE vs JEPIPINE vs OPINE vs KOPINE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.